


available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



European Association of Urology



## Letter to the Editor

**Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7**

Assel et al. [1] recently presented data on the time from elevated prostate-specific antigen (PSA) to prostate cancer diagnosis. They found that men diagnosed with high-grade disease had a longer time from elevated PSA to diagnosis, and conclude that Gleason grade progresses. We believe that the data they presented do not support such an inference.

The article did not describe the time period or the source of Gleason grade information. Gleason grading has changed dramatically over time, with more patients assigned a higher grade in recent years [2]. Without contemporaneous re-review of the original biopsy tissue, changes in grading practice alone would lead to the appearance of more high-grade cases being diagnosed later in time, further from the baseline PSA measurement.

As the authors point out, age is associated with higher Gleason grade, but this does not mean that grade progresses within an individual. Since the participants were (of course) older at later times in the study, it is possible that some had undiagnosed low-grade tumors early in the study and then developed separate high-grade tumors diagnosed at an older age; however, the lower-grade tumors could still be present.

This study calls attention to the challenges of attempting to answer the question of Gleason progression within individuals. As the authors note, repeat biopsy studies showing upgrading in active surveillance patients could be due to initial undersampling. This apparent upgrading could also be affected by differences in patients who return for a follow-up biopsy, as well as the increasing risk of new high-grade tumors with increasing age.

We previously explored this topic using a population-based approach [3]. Widespread adoption of PSA screening led to a remarkable reduction in the incidence of advanced

prostate cancer at diagnosis (stage shift). Since stage progression occurs, we reasoned that Gleason progression, if present, would also be revealed by a parallel decrease in the incidence of high-grade disease. We found that despite the extreme changes in clinical stage over decades, the incidence of high-grade disease (on the basis of pathologist re-review) remained fairly constant over decades within our cohorts. This suggests that Gleason grade progression is not common, although we cannot rule out its occurrence in rare individuals.

Additional pathology evidence suggests that grade does not progress. Prostate cancer is multifocal, and grade can appear to increase with the development of a new, higher-grade tumor focus. Adjacent tumor foci of different grades can have different molecular profiles suggesting that they arose independently, and that the higher grade did not progress from the lower grade. Metastases typically have the same grade as the primary tumor; an autopsy study found no difference in cellular differentiation between the primary tumor and metastases [4].

The question of Gleason progression is of major importance for the treatment of prostate cancer; if Gleason grade does progress, then radical treatment of low-grade disease has a stronger rationale. However, current data do not strongly support Gleason grade progression.

*Conflicts of interest:* The authors have nothing to disclose.

## References

- [1] Assel M, Dahlin A, Ulmert D, et al. Association between lead time and prostate cancer grade: evidence of grade progression from long-term follow-up of large population-based cohorts not subject to prostate-specific antigen screening. *Eur Urol* 2018;73:961–7.
- [2] Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does  $3 + 4 = 4 + 3$ ? *J Clin Oncol* 2009;27:3459–64.
- [3] Penney KL, Stampfer MJ, Jahn JL, et al. Gleason grade progression is uncommon. *Cancer Res* 2013;73:5163–8.
- [4] Taylor HC, Lefkowitz M, Skoog SJ, Miles BJ, McLeod DG, Coggin JT. Intracranial metastases in prostate cancer. *Cancer* 1984;53:2728–30.

DOI of original article: <https://doi.org/10.1016/j.eururo.2018.10.003>.

<https://doi.org/10.1016/j.eururo.2018.10.004>

0302-2838/© 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Kathryn L. Penney<sup>a,b,\*</sup>  
Massimo Loda<sup>c,d,e</sup>  
Meir J. Stampfer<sup>a,b,f</sup>

<sup>e</sup>The Broad Institute, Cambridge, MA, USA

<sup>f</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>a</sup>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

<sup>b</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>c</sup>Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA

<sup>d</sup>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

\*Corresponding author. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA.

Tel.: +1-617-525-0860.

E-mail address: [kpenney@hsph.harvard.edu](mailto:kpenney@hsph.harvard.edu) (K.L. Penney).

October 1, 2018